AstraZeneca Annual Report 2023. Available at: https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2023/pdf/AstraZeneca_AR_2023.pdf. [Last accessed: April 2024]. AstraZeneca plc. FY and Q4 2023 ...
Economic, competitive, governmental, technological and other factors that may affect AstraZeneca's and Alexion's operations are discussed in the section entitled "Risk Factors," in each of AstraZeneca's Annual Report on Form 20-F for the year ended 31 December 2019, and Alexion...
AstraZeneca is a global, science-led biopharmaceutical business and our innovative medicines are used by millions of patients worldwide.
The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and ...
AstraZeneca's market cap is currently ―. The company's EPS TTM is $2.095; its P/E ratio is 32.54; and it has a dividend yield of 2.13%. AstraZeneca is scheduled to report earnings on February 6, 2025, and the estimated EPS forecast is $1.06. See an overview of income statement, ...
And I'm happy to report that we've been able to deal with the challenges. And since we've lastly put it on a [Audio gap] there has not been any meaningful changes in the target capacity on the supply chains that we have set up. So as Pascal have spoke about, what's really impor...
The Global Microbiology Testing or Clinical Microbiology Market is poised to value over USD 9.2 billion by 2027 end at a CAGR of over 10.6% during the forecast period 2020 to 2027. Microbiology Testing or Clinical Microbiology report provides a comprehensive analysis of competitive factors, consumer...
AstraZeneca PLC (AZN) has a Smart Score of 10 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity.
Mantle cell lymphoma (MCL) is an aggressive B-cell non-Hodgkin lymphoma (NHL) with poor prognosis.1,2,3,4MCL accounts for approximately 3% to 6% of new NHL cases in Western countries each year, with an annual incidence of 0...
These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended December 31, 2020, and the most recent Form 10-Q quarterly filing, which are on file with the SEC. Copies of these and other documents are available...